Ursodeoxycholic Acid (URSO)

DRUG3 trials

Sponsors

Intercept Pharmaceuticals, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Chang Gung Memorial Hospital

Conditions

Breast CancerLiver CirrhosisLiver Cirrhosis, Biliary

Phase 2

Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

TerminatedNCT00550862

Intercept PharmaceuticalsLiver Cirrhosis, Biliary

Start: 2007-10-31End: 2010-12-31Updated: 2024-02-06

PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer

Not yet recruitingNCT06842472

Cancer Institute and Hospital, Chinese Academy of Medical SciencesBreast Cancer

Start: 2025-02-28End: 2029-12-31Target: 70Updated: 2025-02-24

Unknown Phase

Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response

Enrolling by invitationNCT07102979

Chang Gung Memorial HospitalLiver Cirrhosis

Start: 2025-09-01End: 2025-12-31Target: 150Updated: 2025-08-07

Related Papers

Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

2014-12-11419 citations